Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $20.9 million.

  • Collegium Pharmaceutical's Change in Receivables rose 1091368.42% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 14206.93%. This contributed to the annual value of $4.4 million for FY2024, which is 22281.58% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Change in Receivables of $20.9 million as of Q3 2025, which was up 1091368.42% from -$15.7 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Change in Receivables registered a high of $58.9 million during Q3 2021, and its lowest value of -$43.2 million during Q4 2021.
  • Over the past 5 years, Collegium Pharmaceutical's median Change in Receivables value was -$106000.0 (recorded in 2024), while the average stood at $2.7 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 72963.23% in 2021, then skyrocketed by 1091368.42% in 2025.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Change in Receivables stood at -$43.2 million in 2021, then skyrocketed by 71.54% to -$12.3 million in 2022, then skyrocketed by 81.06% to -$2.3 million in 2023, then soared by 95.44% to -$106000.0 in 2024, then skyrocketed by 19841.51% to $20.9 million in 2025.
  • Its Change in Receivables was $20.9 million in Q3 2025, compared to -$15.7 million in Q2 2025 and $170000.0 in Q1 2025.